An EU-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HR+/HER2- breast cancer. Key assets highlighted include Enhertu, Keytruda, Verzenio, Kisqali, and Orserdu. 

This interview was conducted on 1 August 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.